Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 16 bp deletion in exon6 and 1 bp insertion in exon6.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-TAP2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
TAP2 also known as Transporter 2 ATP Binding Cassette Subfamily B Member has a mass of approximately 76 kDa. It functions as a part of the peptide-loading complex where it plays a mechanical role in transporting antigen peptides into the endoplasmic reticulum. TAP2 is expressed primarily in antigen-presenting cells such as B cells dendritic cells and macrophages. It is an integral membrane protein located in the membrane of the endoplasmic reticulum.
Biological function summary
The TAP2 protein operates as an important component of the immune system by facilitating the processing and presentation of antigens. It partners with TAP1 and forms a heterodimer complex essential for the transportation of peptides that are 8-16 amino acids long. This action is fundamental for the proper presentation of antigens on major histocompatibility complex (MHC) class I molecules which are pivotal in the recognition of infected or abnormal cells by cytotoxic T lymphocytes.
Pathways
The TAP2 protein plays a significant role in the antigen processing and presentation pathways. It directly impacts the MHC class I pathway by aiding in the selection and transport of peptides that bind to MHC class I molecules. TAP2 functions alongside related proteins such as TAP1 and tapasin which help facilitate the loading of these peptides onto MHC class I molecules in the endoplasmic reticulum preparing them for cell surface presentation.
Mutations or deficiencies in the TAP2 gene are associated with bare lymphocyte syndrome type 1 (BLS1) a rare immunodeficiency disorder. This syndrome relates to a shortage of antigen presentation on MHC class I molecules leading to increased susceptibility to viral infections. TAP2 along with its partner protein TAP1 is critical in maintaining regular immune surveillance and any disruption in their function can result in profound immunological consequences including impaired cytotoxic T cell responses.
